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Background: Diwu Yanggan (DWYG) is a Chinese compound herbal preparation which consists of five Chinese
herbs. This study investigates the preventative effects of DWYG on liver fibrosis induced by carbon tetrachloride
(CCl4) and explores its possible mechanisms of action.
Methods: Liver fibrosis was induced in male Wistar rats by injecting a 50% CCl4/soybean oil solution subcutaneously
twice a week for six weeks. After six weeks of treatment, serum aspartate transaminase (AST) and alanine transaminase
(ALT) assay, liver tissue histological assessment and hepatic hydroxyproline assay were respectively carried out to
examine the effects of DWYG on liver function and fibrosis degree. The impacts of DWYG on the expression levels of
epithelial marker E-cadherin, mesenchymal marker Vimentin, transforming growth factor β1 (TGF-β1) and bone
morphogenetic protein-7 (BMP-7) were further examined by quantitative real-time RT-PCR and Western blot analysis. In
addition, the differences of Hedgehog (Hh) signaling pathway activity between DWYG-treated and DWYG-untreated
fibrotic liver tissues were also evaluated by quantitative real-time RT-PCR and Western blot analysis.
Results: Upon DWYG treatment, the serum levels of ALT and AST, hepatic hydroxyproline content and the degree of
fibrosis in CCl4-induced fibrotic model rats were dramatically declined. In accompany with the alleviation of the
degree of fibrosis, DWYG treatment provoked the reversal of epithelial-to-mesenchymal transition (EMT) to
mesenchymal-to-epithelial transition (MET) in the fibrotic liver tissues, which was characterized with the
up-regulation expression of E-cadherin and down-regulation expression of Vimentin. Furthermore, we observed
that the expression level of TGF-β1 was reduced whereas the expression level of BMP-7 was enhanced in liver tissues of
DWYG-treated rats, therefore the expression ratio of TGF-β1/BMP-7 was dramatically decreased compared to CCl4-induced
fibrosis model rats. In addition, quantitative real-time RT-PCR and Western blot analysis demonstrated that after DWYG
treatment the expressions of Hh ligand Shh, receptor Smo and Ptc, and transcription factor Gli1 in CCl4-induced fibrotic
liver tissues were dramatically repressed.
Conclusions: DWYG demonstrates therapeutic potential to prevent liver fibrosis by modulating the balance between
EMT and MET through reducing the expression ratio of TGF-β1/BMP-7 and inhibiting the excessive activation of Hh
signaling pathway.
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Liver fibrosis is a wound-healing process that responds
to diverse types of chronic liver injuries, such as viral in-
fection, alcoholic, drug or chemical toxicity. The persist-
ent activation of wound healing responses causes the
unbalanced extracellular matrix (ECM) deposition and
resolution, and could result in progression to cirrhosis,
liver failure, and portal hypertension, which are often as-
sociated with considerable morbidity and mortality [1].
Emerging anti-fibrotic therapies are aimed at inhibiting
the accumulation of fibrogenic cells and/or preventing
the deposition of extracellular matrix proteins. Although
many therapeutic interventions are effective in experi-
mental models of liver fibrosis, their efficacy and safety
in human are not always satisfactory [2]. This highlights
the urgent need to both increase our understanding of
the mechanisms of liver fibrogenesis and develop novel
therapies to arrest or reverse the fibrotic process as even
advance fibrosis is reversible [3,4].
Recently, the role of epithelial-to-mesenchymal transi-
tion (EMT) in hepatic fibrogenesis as an evolving patho-
genetic concept has drawn extensive attention. EMT is
defined as the biological process by which cells gradually
lose typical epithelial characteristics and acquire me-
senchymal traits, which is of crucial importance not only
during embryonic development but also in adult tissue re-
modeling [5]. In chronic liver diseases emerging evidences
suggest that activated hepatic stellate cells were not the
only key players in the hepatic fibrogenic process and that
other cell types, either hepatic (i.e. hepatocyte, biliary epi-
thelial cell and portal fibroblast) or extra-hepatic (bone
marrow-derived cells and circulating fibrocytes) could con-
tribute to this process through EMT [6-8]. Moreover,
mesenchymal-to-epithelial transition (MET), as the reverse
process of EMT, indicates the transformation of mesen-
chymal cells to acquire epithelial traits. MET has long been
known to be of paramount importance in normal embry-
onic development, but has only recently been shown to
represent an attractive concept in counteracting fibrotic
damage in acute and chronic renal disease processes [9]. In
vitro and in vivo studies have reported that the EMT-
derived mesenchymal cells could be reverted to epithelial
cells that ultimately become hepatocytes or cholangiocytes
through the exogenous regulation of MET in liver fibro-
genic injury [10,11]. The important roles of EMT and
MET in liver tissue injury and repair, in addition to their
potential reversibility, made this trans-differentiation
process a relevant and suitable target for anti-fibrogenic
strategies in liver fibrosis. Furthermore, this trans-
differentiation process is known to be tightly controlled by
modulating factors, such as TGF-β1, BMP-7 and Hh sig-
naling. Therapeutic manipulations of these known modu-
lating factors have generally been demonstrated to
influence liver regeneration and fibrosis in rodents [12].Diwu Yanggan capsule (DWYG) has been invented as a
new anti-fibrotic medicine, and consists of five Chinese
medicinal herbal extracts. In clinical study, we observed
that DWYG could have significantly hepato-protective ef-
fects on the patients with chronic hepatitis B infections as
evidenced by the results of an obvious decrease in serum
ALT and AST levels [13]. More importantly, the results of
percutaneous liver biopsy demonstrated that DWYG
could effectively decrease the degree of fibrosis in the pa-
tients with chronic hepatitis B infection, suggesting it
might be an effective antagonist of liver fibrosis (data not
shown). Following pharmacological studies showed that
DWYG could decrease the serum levels of many cytokines
in the patients with chronic hepatitis B infection, parti-
cularly TGF-β1 and IL-6 (data not shown). In addition,
the active constituent of DWYG, such as curcumin, has
already been reported to block the activation of Hh signal-
ing pathway through inhibiting Shh expression [14]. How-
ever, the underlying therapeutic mechanisms of DWYG
on liver fibrosis still remain obscure even though it has
shown to provide clear therapeutic benefit.
Based on the above mentioned information, in this study
we investigated the effects of DWYG on carbon tetra-
chloride (CCl4)-induced hepatic fibrogenesis during the
initial phases in rats. Moreover, we clarified the impacts of
DWYG on the trans-differentiation process of EMT/MET,
and to further explore its potential modulation mechan-
ism we analyzed the effects of DWYG on the activities of
TGF-β1, BMP-7 and Hh signaling pathway, which con-
tributed to explain its underlying therapeutic mechanism.
Methods
Characterization and preparation of herbal compound
The Chinese herbal medicine formula DWYG is a new
drug authorized by the Hubei Food and Drug Administra-
tion (Grant No. Z20113160). The mixture includes five
Chinese medicinal herbal extracts, whose proportions (w/
w) are as follows: Rehmannia glutinosa (Gaertn.) DC.
20.0%; Artemisia scoparia Waldst. & Kitam. 33.3%;
Curcuma longa L. 13.4%; Schisandra chinensis (Turcz.)
Baill. 20.0%; Glycyrrhiza uralensis Fisch. 13.4%. The DWYG
capsules used in this study with the same batch number
(20120221) were provided by Traditional Chinese Medicine
Preparation Room of Hubei Provincial Hospital of
Traditional Chinese Medicine. Briefly, the DWYG capsules
were prepared as follows: The decoction of Rehmannia glu-
tinosa (Gaertn.) DC. and Glycyrrhiza uralensis Fisch., the
coarse powder of Schisandra chinensis (Turcz.) Baill., Arte-
misia scoparia Waldst. & Kitam. and Curcuma longa L.
were mixed together, then added 75% ethanol and extracted
by reflux extraction three times. The ethanol extracts were
filtrated, concentrated and removed ethanol by reduced
pressure. The DWYG capsules were finally obtained by de-
compression drying and granulating of the above refined
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in normal saline and its final concentration was 36 mg/mL.
Two representative components that might chemically rep-
resent characteristic components of herbal medicines for
quality control were determined by high-performance li-
quid chromatography (HPLC) and shown in Figure 1.
Animal experiments
Male Wistar rats (SPF class, weighing 200–250 g) were
purchased from the Hubei Experimental Animal Center
of the Chinese Academy of Sciences (Wuhan, China).
All rats were housed with a 12 h-light–dark cycle and
with water and standard chow ad libitum. The rats were
randomly divided into three treatment groups: CCl4-in-
duced model group (n = 6), DWYG-treated group (n = 6)
and blank control group (n = 6). In the CCl4-induced
model group, rats were treated with subcutaneous injec-
tions of CCl4 (suspended at 50% in soybean oil, 1 mL/
kg) for 6 weeks; In the DWYG-treated group, besides
the subcutaneous injections of 50% CCl4/soybean oil
twice a week, rats were simultaneously treated withFigure 1 Two representative components (Chlorogenic: A1-A3; Diammo
were determined by high-performance liquid chromatography (HPLC).intragastric administrations of the solution of DWYG
capsules (suspended in normal saline, 360 mg/kg) once a
day for 6 weeks; and in blank control group, rats were
treated with both subcutaneous injections of soybean oil
(1 mL/kg, twice a week) and intragastric administrations
of normal saline (the same volume as that of the solu-
tion of DWYG capsules given in the DWYG-treated
group) once a day for 6 weeks. All rats were sacrificed
and serum was collected for serum enzyme analysis, and
then liver pieces were fixed in 10% neutral buffered for-
malin or snap frozen in liquid nitrogen for further ana-
lysis. The protocols of all animal experiments were
approved by the Hubei Provincial Laboratory Animal
Care and Use Commission.
Determination of serum ALT and AST activities
Serum concentrations of aspartate transaminase (AST)
and alanine transaminase (ALT) in different treatment
groups were measured using rat ELISA kits commer-
cially available from Shanghai Westang Bio-tech CO.,
LTD according to the manufacturer’s instructions.nium glycyrrhizinate: B1-B3) of DWYG capsules for quality control
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Hepatic hydroxyproline content was quantified colori-
metrically in flash frozen liver tissue samples of different
treatment groups as described by Lee et al. [15]. Briefly,
30 mg liver tissue samples were hydrolyzed in 6 mol/L
HCl at 120°C for 16 h. After centrifugation, the super-
natant was removed and neutralized with 6 mol/L
NaOH. The solution was oxidized with Chloramine T
(Sigma-Aldrich Corp., St Louis, MO, United States) in
acetate/citrate buffer, followed by the addition of Ehrlich’s
solution. The final mixture was incubated at 60°C for
30 min and then at room temperature for 10 min. Absorb-
ance was determined at 560 nm. The value of the hepatic
hydroxyproline concentration was expressed as μg/g wet
liver tissue.
Liver histology and morphometry
Liver tissue samples of different treatment groups were
fixed in 10% neutral buffered formalin, paraffin-embedded,
and sectioned at 5 μm. For standard histology, liver sec-
tions were stained with Hematoxylin-eosin (H & E) and
Masson’s trichrome and then analyzed blindly as described
previously [16]. Collagen staining of liver sections with
Masson’s trichrome was assessed by morphometric ana-
lysis (Image-Pro Plus 6.0 software, Media Cybernetics,
USA). Ten randomly chosen × 20 fields/section were eval-
uated for each mouse.
RNA isolation and quantitative real-time RT-PCR
Total RNA was isolated from the liver tissue samples of dif-
ferent treatment groups with TRIzol Reagent (Invitrogen)
according to the manufacturer’s protocol. RNase-free
DNase (Promega) was used to eliminate the contamination
of genomic DNA. The first cDNA strand was synthesized
by using a ReverTra Ace qPCR RT Kit (Toyobo, Japan),
and then amplified using THUNDERBIRD SYBR qPCR
Mix (Toyobo, Japan) and specific primers on the Mx3000P
QPCR System (Stratagene, USA). Primer sequences are
listed in Table 1 and the housekeeper gene GAPDH was
used as an internal control. Target gene levels in the sam-
ples are presented as a ratio of levels in treated tissues to
levels detected in corresponding control tissues according
to the 2-ΔΔCt method [17].
Western blotting
Total protein was extracted by homogenizing liver tissue
samples of different treatment groups in lysis buffer
(50 mM Tris, pH 7.2, 1% Triton X-100, 0.5% sodium
deoxycholate, 0.1% SDS, 500 mM NaCl, 10 mM MgCl2,
with 1 mM PMSF). Then, the proteins were separated
by 8-12% SDS-PAGE and transferred onto polyvinylide-
nedi fluoride membrane. The membranes were blocked
with 5% defatted milk and probed with specific primary
anti-Vimentin, TGF-β1, BMP-7, Shh, Gli1, Ptc and Smoantibodies (Santa Cruz Biotechnology) or anti-E-cadherin
antibody (Abcam), and followed by horseradish peroxidase
(HRP)-conjugated goat anti-mouse or rabbit anti-goat IgG
secondary antibodies (Santa Cruz Biotechnology). The
membranes were then incubated with enhanced chemilu-
minescent substrate (Santa Cruz Biotechnology) before
being exposed to film.
Statistical analysis
Statistical significance of the data was calculated by
One-way ANOVA or Student’s t-test. A significance level
of p < 0.05 was chosen.
Results
DWYG treatment inhibited collagen deposition and tissue
damage in the livers of rats induced by CCl4
To evaluate the protective effects of DWYG on CCl4-in-
duced liver injury in rats, we examined the histological
changes of liver tissues in different treatment groups
through H & E staining. As presented in Figure 2A, nor-
mal lobular architecture with central veins and radiating
hepatic cords was shown in the liver tissue section of
blank control groups. Upon chronic CCl4 exposure, lob-
ules of liver in model group rats were disorder with a
pile of deposition of fibrous tissue, steatosis and necrosis
in hepatocytes, whereas DWYG treatment significantly
ameliorated the pathological changes observed on CCl4-
induced injury. Moreover, we detected changes of the
serum ALT and AST levels in rats of different treatment
groups. As important markers to evaluate liver function,
the serum levels of AST and ALT in CCl4-induced
model group substantially elevated compared with blank
control group (Figure 2B, #p < 0.05), while DWYG treat-
ment significantly inhibited the increase in serum levels
of ALT and AST induced by CCl4 (Figure 2B, *p < 0.05).
These data suggested that DWYG treatment could
ameliorate liver injury and restore liver function.
Chronic CCl4 exposure is known to induce progressive
fibrogenic liver injury [18]. To investigate the potential im-
pacts of DWYG on the degree of CCl4-induced liver fibro-
sis in rats, we examined the fibrogenic changes of liver
tissues in different treatment groups through Masson’s
trichrome staining. Figure 2C showed that no fibrous
septum was observed in liver tissues of blank control
group, whereas fibrous septa became apparent following
fibrosis induced by CCl4. After DWYG treatment, the de-
gree of liver fibrosis induced by CCl4 was dramatically al-
leviated. Further morphometric analysis based on the
Masson’s trichrome staining of liver sections in different
treatment groups verified these above observations. As
shown in Figure 2D, the relative fibrosis area of CCl4-in-
duced model group was obviously increased from 1.41 ±
0.36% to 8.10 ± 0.92% (#p < 0.05), whereas the relative fi-
brosis area of DWYG treatment group was drastically
Table 1 Primer sequences
Gene Forward sequence Reverse sequence Product size (bp)
E-cardherin 5′-GGGTTGTCTCAGCCAATGTT-3′ 5′-CACCAACACACCCAGCATAG-3′ 184
Vimentin 5′-AGATCGATGTGGACGTTTCC-3′ 5′-CACCTGTCTCCGGTATTCGT-3′ 205
TGF-β1 5′-GCTGAACCAAGGAGACGGAAT-3′ 5′-CGGTTCATGTCATGGATGGTG-3′ 143
BMP-7 5′-GAGGGCTGGTTGGTATTTGA-3′ 5′-AACTTGGGGTTGATGCTCTG-3′ 121
Shh 5′-CTGGCCAGATGTTTTCTGGT-3′ 5′-TAAAGGGGTCAGCTTTTGG-3′ 117
Glil 5′-AACTCCACGAGCACACAGG-3′ 5′-GCTCAGGTTTCTCCTCTCTC-3′ 79
Smo 5′-GCCTGGTGCTTATTGTGG-3′ 5′GGTGGTTGCTCTTGATGG-3′ 75
Ptc 5′-AGCGTACCTCCTCCTAGGTAAGCCTC-3′ 5′-CGGCTTTATTCAGCATTTCCTC-3′ 122
GAPDH 5′-TGTTGCCATCAACGACCCCTT-3′ 5′-CTCCACGACATACTCAGCA-3′ 202
Figure 2 DWYG treatment inhibited collagen deposition and tissue damage in the livers of rats induced by CCl4. Paraffin-embedded liver
sections of different treatment groups were stained by H & E (A) (original magnification, ×200) and Masson’s trichrome (C) (original magnification, ×100) as
described in Materials and methods. Representative micrographs are displayed. (B) The serum levels of aspartate transaminase (AST) and alanine
transaminase (ALT) in different treatment groups were respectively detected by commercial ELISA kits. Data represent the means and standard deviation of
3 independent experiments. #p< 0.05 vs. blank control group, *p< 0.05 vs. CCl4-induced model group. (D) The relative fibrosis areas were evaluated by
morphometric analysis of Masson’s trichrome-stained liver tissue sections from different treatment groups. Data represent the means and standard
deviation of 3 independent experiments. #p< 0.05 vs. blank control group, *p< 0.05 vs. CCl4-induced model group. (E) Hepatic hydroxyproline content of
different treatment groups was assessed as described in Materials and methods. Data represent the means and standard deviation of 3
independent experiments. #p< 0.05 vs. blank control group, *p< 0.05 vs. CCl4-induced model group.
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indicating that DWYG had an inhibitory effect on the pro-
gressive fibrogenic liver injury induced by CCl4. Further-
more, we evaluated the hydroxyproline content of liver
tissues in different treatment groups. Essentially, all of the
hydroxyproline in animal tissues is exclusively found in
collagen [19], so the content of hydroxyproline can be
considered as an indicator of collagen amount. As indi-
cated in Figure 2E, CCl4 induced a considerable elevation
in the level of hydroxyproline at 6 weeks (from 135.12 ±
17.74 μg/g wet liver tissue to 207.39 ± 31.66 μg/g wet liver
tissue, #p < 0.05), while the hydroxyproline content of liver
tissues after DWYG treatment was obviously reduced
from 207.39 ± 31.66 μg/g wet liver tissue to 155.16 ±
25.22 μg/g wet liver tissue (*p < 0.05). This result was con-
sistent with the inhibitory effect of DWYG on the progres-
sive fibrogenic liver injury based on the histological and
morphometric analysis of Masson’s trichrome staining,Figure 3 DWYG treatment inhibited EMT and promoted MET in the fi
levels of E-cadherin and Vimentin in the liver tissues of different treated gr
was calculated as described in Materials and methods, considering GAPDH
represent the means and standard deviation of 3 independent experiment
levels of E-cadherin and Vimentin in the liver tissues of different treated gr
used as control for equal protein loading. Selected blots from one typical e
analysis of the bands in 3 independent experiments. #p < 0.05 vs. blank conconfirming that DWYG could inhibit the collagen accu-
mulation in liver tissues of CCl4-induced fibrotic rats.
DWYG treatment inhibited EMT and promoted MET in the
fibrotic livers of rats induced by CCl4
To ascertain the potential impacts of DWYG on the
EMT and MET in the fibrotic livers of rats induced by
CCl4, we detected changes in the expression levels of
epithelial marker E-cadherin and mesenchymal marker
Vimentin by quantitative real-time RT-PCR and Western
blot analysis. As indicated in Figure 3A, the mRNA ex-
pression levels of E-cadherin and Vimentin in liver tis-
sues of blank control rats were respectively assigned as
the baseline levels. After CCl4 induction for 6 weeks, the
mRNA expression level of E-cadherin in liver tissues of
fibrotic model rats was about 60% lower than the base-
line level, while the mRNA expression level of Vimentin
was about 2.5-fold higher than the baseline level.brotic livers of rats induced by CCl4. (A) The mRNA expression
oup rats were detected by quantitative real-time RT-PCR. Delta-delta-CT
as internal control and blank control group as reference control. Data
s. *p < 0.05 vs. CCl4-induced model group. (B) The protein expression
oup rats were analyzed by Western blotting. Anti-β-actin blotting was
xperiment are presented. The bar graph represents the densitometric
trol group, *p < 0.05 vs. CCl4-induced model group.
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level, Western blot analysis also demonstrated that com-
pared with blank control group the content of Vimentin
protein in liver tissues of fibrotic model rats increased dra-
matically, whereas the protein expression of E-cadherin in
rat liver tissues virtually disappeared after CCl4 induction
(Figure 3B, #p < 0.05), suggesting that EMT occurred in
the evolution of CCl4-induced fibrosis. Following treat-
ment with DWYG, the expression pattern of the above
epithelial and mesenchymal markers in liver tissues of
CCl4-induced fibrotic rats was changed. Figure 3A pre-
sented that DWYG-treated rats expressed significantly less
level of Vimentin mRNA in liver tissues but dramatically
greater level of E-cadherin mRNA than those of CCl4-in-
duced fibrotic rats (*p < 0.05). Additional Western blot
analysis verified that the increase of E-cadherin mRNA in
liver tissues of DWYG-treated rats was accompanied by
accumulation of the protein, whereas the decrease of
Vimentin mRNA was accompanied by diminished protein
(Figure 3B, *p < 0.05). These results revealed that DWYGFigure 4 DWYG treatment recovered the expression ratio of TGF-β1 a
mRNA expression levels of TGF-β1 and BMP-7 in the liver tissues of differen
Delta-delta-CT was calculated as described in Materials and methods, cons
control. Data represent the means and standard deviation of 3 independen
expression levels of TGF-β1 and BMP-7 in the liver tissues of different treate
blotting was used as control for equal protein loading. Selected blots from
densitometric analysis of the bands in 3 independent experiments. *p < 0.0
(C) The mRNA and protein expression ratios of TGF-β1/BMP-7 in the DWYG
analyzed. Data represent the means and standard deviation of 3 independ
CCl4-induced model group.treatment could reverse EMT and promote MET during
the progression of fibrosis induced by CCl4.
DWYG treatment recovered the expression ratio of TGF-β1
and BMP-7 in the fibrotic livers of rats induced by CCl4
TGF-β1 is believed to play a central role in regulating
organ fibrosis. BMP-7, however, a member of the TGF-β1
superfamily, counteracts the fibrogenic action of TGF-β1
[20]. The potential effects of DWYG on TGF-β1 and
BMP-7 expression levels in livers of rats induced by CCl4
were assessed by quantitative real-time RT-PCR and
Western blotting analysis. As shown in Figure 4A, follow-
ing 6 weeks CCl4 induction, the substantial increases of
TGF-β1 mRNA and protein expression were observed.
Meanwhile, the mRNA and protein expression levels of
BMP-7 were dramatically down-regulated in the fibrotic
livers. However, DWYG treatment significantly reduced
the mRNA expression level of TGF-β1, whereas restored
the expression of BMP-7 by stimulating 1.5-fold increase
in transcript expression levels (Figure 4A, *p < 0.05). Innd BMP-7 in the fibrotic livers of rats induced by CCl4. (A) The
t treated group rats were detected by quantitative real-time RT-PCR.
idering GAPDH as internal control and blank control group as reference
t experiments. *p < 0.05 vs. CCl4-induced model group. (B) The protein
d group rats were analyzed by Western blotting. Anti-β-actin
one typical experiment are presented. The bar graph represents the
5 vs. blank control group, **p < 0.05 vs. CCl4-induced model group.
-treated and CCl4-induced fibrotic liver tissues were statistically
ent experiments. *p < 0.05 vs. CCl4-induced model group, #p < 0.05 vs.
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these changes in TGF-β1 and BMP-7 transcript expression
were paralleled by 3-fold decrease in TGF-β1 protein ex-
pression and 6.7-fold increase in BMP-7 protein expres-
sion after DWYG treatment (Figure 4B, **p < 0.05). A
reversed expression ratio of TGF-β1/BMP-7 in fibrotic tis-
sues could be deemed as an anti-fibrotic phenotype [9],
thus we further analyze the impact of DWYG on the ex-
pression ratio of TGF-β1/BMP-7 in CCl4-induced fibrotic
liver tissues. Regardless of the mRNA and protein ex-
pression levels, the ratio of TGF-β1/BMP-7 in fibrotic
livers induced by CCl4 was declined by DWYG treatment
(Figure 4C, *p < 0.05 and #p < 0.05). These opposite effects
on the protein and mRNA levels of TGF-β1 and BMP-7
suggested that DWYG treatment could prevent CCl4-in-
duced liver fibrosis in rats through recovering the ratio of
TGF-β1/BMP-7.
DWYG treatment inhibited the excessive activation of Hh
signaling in the fibrotic livers of rats induced by CCl4
To assess the mechanism by which DWYG treatment
regulate EMT/MET in CCl4-induced rat, we focused our
investigation on Hh signaling because it has been impli-
cated in the regulation of EMT [21]. Consistent with pre-
viously published reports [22], the protein expression of
Shh and Gli1 was negligible in liver tissues of blank con-
trol rats (Figure 5B). After CCl4 induction for six weeks,
there was a robust up-regulation of Shh, Smo and Ptc
transcript expression concomitant with a substantial up-
regulation of Gli1 mRNA compared with blank control
group (Figure 5A). Western blot analysis revealed that
changes of the above molecules in mRNA expression were
accompanied by coincident changes in protein expression
(Figure 5B), confirming that Hh signaling pathway was ac-
tivated in the evolution of liver fibrosis. Moreover, follow-
ing DWYG treatment, the expression of Shh and Gli1 in
mRNA levels drastically reduced compared to that of rats
treated with CCl4 alone (Figure 5A, *p < 0.05). The down-
regulation of these proteins in mRNA expression level was
matched by a decrease in hepatic Shh and Gli1 protein ex-
pression assessed by Western blot analysis of whole liver
tissue (Figure 5B). Additionally, the robust increases of
Smo mRNA and protein expression in untreated CCl4-in-
duced fibrotic rats were considerably diminished after
DWYG treatment. Meanwhile, the expression of its co-
receptor Ptc at both mRNA and protein levels were
correspondingly diminished (Figure 5B, *p < 0.05). These
findings suggested that DWYG treatment could inhibit
the excessive activation of Hh signaling in the fibrotic
livers of rats induced by CCl4.
Discussion
In recent years, liver fibrosis is gradually regarded as the
result of repair and remodel of various liver injuries. Theoutcome of liver injury is dictated by the effectiveness of
repair. Choi SS and Diehl AM put forward the hypoth-
esis that the balance between EMT and MET modulates
the outcome of chronic liver injury. When EMT activity
outstrips MET, repair is mainly fibrogenic, causing liver
fibrosis; conversely, predominance of MET favors more
normal liver regeneration [12]. In this study, our data
also demonstrated that the fibrogenesis of CCl4-induced
chronic liver injury accompanied with the occurrence of
EMT, one of the key hallmarks of which is loss of E-
cadherin; And the treatment with DWYG could result in
the reversal of EMT to MET in the fibrotic liver tissue,
which was characterized with the up-regulation of E-
cadherin expression and down-regulation of Vimentin
expression, in accompany with the alleviation of the de-
gree of fibrosis. Herein, the anti-fibrotic mechanism of
DWYG is associated with the modulation of the balance
between EMT and MET.
Moreover, liver fibrosis is also a complex pathophysio-
logical process involving the multi-link, multi-factor and
multi-channel damage [2]. Chemical drugs are generally
difficult to achieve significant therapeutic results used
alone because of its single therapeutic target [23]. Ex-
perimental reports and clinical applications of traditional
Chinese medicines against liver fibrosis are in the as-
cendant due to their effects on multiple targeting and
multidirectional regulations [24]. In this study, our data
showed that DWYG treatment could modulate the
balance between EMT and MET through at least two
different mechanisms: reducing the expression ratio of
TGF-β1/BMP-7 and inhibiting the excessive activation
of Hh signaling pathway.
TGF-β1, as one of the key mediators of fibrogenesis, is
considered as the master regulator of EMT. TGF-β1 can
induce EMT in various types of cultured nonmaliganant
and malignant epithelial cells, including hepatocyte and
cholangiocyte, through different signaling mechanisms
[20]. Our data also demonstrated that the expression
level of TGF-β1 in the CCl4-induced fibrotic liver tissue
was dramatically elevated, and then obvious EMT was
provoked in the fibrotic liver tissue. Moreover, BMP-7, a
member of the TGF-β surperfamily that antagonizes
TGF-β1 signaling, negatively regulates TGF-β1-induced
EMT in different types of organ injury, including liver fi-
brosis. Both pharmacological administration and genetic
expression of BMP-7 have been shown not only to pre-
vent organ fibrotic injury by inhibiting TGF-β-provoked
EMT but also to promote organ recovery by stimulating
the re-population of injured tissues with healthy cells,
partly through inducing MET [25,26]. As evidenced by
our data, the up-regulated expression level of BMP-7
induced the occurrence of MET in the liver tissues of
DWYG-treated rats, which was characterized with the up-
regulated expression level of E-cadherin. These results are
Figure 5 DWYG treatment inhibited the excessive activation of Hh signaling in the fibrotic livers of rats induced by CCl4. (A) The mRNA
expression levels of Shh, Gli1, Ptc and Smo in the liver tissues of different treated group rats were detected by quantitative real-time RT-PCR.
Delta-delta-CT was calculated as described in Materials and methods, considering GAPDH as internal control and blank control group as reference
control. Data represent the means and standard deviation of 3 independent experiments. *p < 0.05 vs. CCl4-induced model group. (B) The protein
expression levels of Shh, Gli1, Ptc and Smo in the liver tissues of different treated group rats were analyzed by Western blotting. Anti-β-actin
blotting was used as control for equal protein loading. Selected blots from one typical experiment are presented. The bar graph represents the
densitometric analysis of the bands in 3 independent experiments. #p < 0.05 vs. blank control group, *p < 0.05 vs. CCl4-induced model group.
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signaling tends to promote EMT, whereas BMP-7 signal-
ing seems not only to counteract EMT, but also to pro-
mote MET, even in adult tissue. Therefore, the expression
ratio of TGF-β1/BMP-7 could be considered as the regula-
tor factor to modulate the balance between EMT and
MET. Our data also demonstrated that DWYG could ob-
viously decrease the expression ratio of TGF-β1/BMP-7 inCCl4-induced fibrotic liver tissue, which facilitated the re-
versal of EMT to MET in liver tissues and attenuated the
degree of liver fibrosis.
Like TGF-β1/BMP-7, Hh signaling also modulates
EMT/MET in adult liver repair and regeneration. Hh
signaling is a key morphogenetic pathway that controls
fetal liver development and also plays an essential role in
the modulation of wound healing responses in many
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quiescent in normal liver, but becomes reactivated as a
repair mechanism in chronic liver injury. However, ex-
cessive or persistent Hh pathway activity actually aborts
successful regeneration of damaged liver tissue and con-
tributes to the pathogenesis of liver fibrosis by promot-
ing EMT (while inhibiting MET) [22]. Our study showed
that chronic exposure to CCl4 activated the Hh signaling
pathway, which was manifested as the elevated mRNA
and protein levels of Hh ligand Shh and transcription
factor Gli1. Meanwhile, during the course of CCl4-in-
duced liver fibrogenesis, the increases of hepatic collagen
content and EMT markers expression in liver tissues of
fibrotic model rats were paralleled by the elevation of
Hh pathway activity, which also proved that the dysregu-
lation of Hh signaling pathway plays a pivotal role in
modulating liver injury and initiation of EMT that accel-
erates the induction of fibrosis [7,27]. After DWYG
treatment, the expressions of Hh ligand Shh, membrane-
spanning receptor Smo and its co-receptor Ptc, and
transcription factor Gli1 in CCl4-induced fibrotic liver
tissue were dramatically repressed, suggesting that the
activity of Hh signaling pathway was inhibited. The in-
hibition of Hh signaling pathway restored the expression
of epithelial marker E-cadherin, repressed the expression
of mesenchymal marker Vimentin and provoked the re-
versal of EMT to MET in CCl4-induced fibrotic liver tis-
sue, which contributed to alleviating the degree of liver
fibrosis.Conclusions
We described the antifibrotic effect of DWYG and its pos-
sible mechanisms on CCl4-induced fibrotic model rats.
Importantly, our study not only underscored that the
modulation of the balance between EMT and MET (inhi-
biting EMT while promoting MET) is a novel strategy for
prevention of fibrotic diseases, but also set a foundation
for the rational utilization of DWYG in combating liver fi-
brosis. Moreover, multiple mechanisms, including redu-
cing the expression ratio of TGF-β1/BMP-7 and inhibiting
the excessive activation of Hh signaling pathway, were in-
volved in modulating the balance between EMT and MET
by DWYG treatment, which further demonstrate the ad-
vantage of traditional Chinese medicine compound with
multi-component and multi-target in the therapy for liver
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